Skip to content
10-Q

Quarterly Report

Edwards Lifesciences Corp EW

0001099800-25-000023

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 586.6M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $597.8M
Long Term Debt Q1 2025 · Dec 31, 2024 $597.7M
Short Term Investments Q1 2025 · Mar 31, 2025 $757.9M
Short Term Investments Q1 2025 · Dec 31, 2024 $930.7M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $3.14B
Cash And Equivalents Q1 2025 · Dec 31, 2024 $3.05B
Stockholders Equity Q1 2025 · Mar 31, 2025 $10.13B
Stockholders Equity Q1 2025 · Dec 31, 2024 $10B
Current Liabilities Q1 2025 · Mar 31, 2025 $1.39B
Current Liabilities Q1 2025 · Dec 31, 2024 $1.51B
Total Liabilities Q1 2025 · Mar 31, 2025 $2.83B
Total Liabilities Q1 2025 · Dec 31, 2024 $2.99B
Current Assets Q1 2025 · Mar 31, 2025 $6.21B
Current Assets Q1 2025 · Dec 31, 2024 $6.29B
Total Assets Q1 2025 · Mar 31, 2025 $13.02B
Total Assets Q1 2025 · Dec 31, 2024 $13.06B
Shares Diluted Q1 2025 · Mar 31, 2024 604.1M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $200K
Capex Q1 2025 · Mar 31, 2024 $65.3M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$53.5M
Eps Diluted Q1 2025 · Mar 31, 2024 $0.58
Eps Basic Q1 2025 · Mar 31, 2024 $0.58
Sga Expense restated Q1 2025 · Mar 31, 2024 $428.4M
Rd Expense restated Q1 2025 · Mar 31, 2024 $256.7M
Net Income Q1 2025 · Mar 31, 2024 $351.9M
Operating Income restated Q1 2025 · Mar 31, 2024 $349M
Gross Profit restated Q1 2025 · Mar 31, 2024 $1.04B
Cost Of Revenue restated Q1 2025 · Mar 31, 2024 $286.9M
Revenue restated Q1 2025 · Mar 31, 2024 $1.33B